Current approaches for new TB drugs
IR@CDRI: CSIR-Central Drug Research Institute, Lucknow
View Archive Info| Field | Value | |
| Creator |
Pandey, Shilpika
Soni, Isha Topno, Neha Dasgupta, Arunava Chopra, Sidharth |
|
| Date |
2015-05-11T07:40:01Z
2015-05-11T07:40:01Z 2014 |
|
| Identifier |
Current Respiratory Medicine Reviews, 2014, 10(2), 88-96
http://hdl.handle.net/123456789/1448 |
|
| Description |
Tuberculosis is essentially a curable disease but inspite of a WHO approved DOTS therapy, it still continues to ravage mankind. This situation is exacerbated by long course of chemotherapy, increasing drug resistance and co-emergence with HIV. The TB drug pipeline remained stagnant for a long time with no new drug approved till FDA approval for Bedaquiline. This situation has now improved with a number of agents in pre-clinical and clinical development against M. tuberculosis. In this review, we are focusing on some of the newer drugs in discovery and preclinical development against M. tuberculosis.
|
|
| Format |
353668 bytes
application/pdf |
|
| Language |
en
|
|
| Relation |
CSIR-CDRI Communication No. 8803
|
|
| Subject |
Clinical Strains
MIC Mycobacterium Drugs Pre-Clinical Development Tuberculosis |
|
| Title |
Current approaches for new TB drugs
|
|
| Type |
Article
|
|